Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness' Stock Picks With Huge Upside Potential
Neurocrine Biosciences Announces Initiation Of Phase 3 Registrational Program for NBI-1117568 As Potential Treatment For Adults With Schizophrenia
Express News | Neurocrine Biosciences Initiates Phase 3 Registrational Program for Nbi-1117568 as Potential Treatment for Adults With Schizophrenia
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192
Earnings Preview: NBIX to Report Financial Results Post-market on May 05
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $179
CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $158
Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?
Neurocrine Price Target Cut to $158.00/Share From $163.00 by Canaccord Genuity
Neurocrine Is Maintained at Buy by Canaccord Genuity
Evercore Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $185
New Analyst Forecast: $NBIX Given 'Buy' Rating
Evercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)
Neurocrine Biosciences Publishes Positive Data From Movement Disorder Study
Neurocrine Announces Publication Of Post-Hoc Analysis From Two 48-Week Studies, KINECT 3 Extension And KINECT 4, Demonstrating Long-term Safety Profile And Robust Efficacy Of INGREZZA Capsules In Adults With TD In The Journal Of Clinical Psychiatry
Express News | Evercore ISI Group Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $185
TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $166
H.C. Wainwright Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $168
Neurocrine Is Maintained at Buy by HC Wainwright & Co.